Breast Cancer Research and Treatment最新文献

{"title":"Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.","authors":"Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radisic, Michelle J Naughton, Georg Pfeiler, Karen Gelmon, Justin M Balko, Daniel Egle, Gabriele Zoppoli, Tiffany Traina, Miguel Martin Jimenez, Silvia Antolin Novoa, Tufia Haddad, Arlene Chan, Alistair Ring, Antonio Wolff, William Fraser Symmans, Jose Ponce Lorenzo, Dhanusha Sabanathan, Hal J Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Meritxell Bellet-Ezquerra, Theodoros Foukakis, Yelena Novik, Gabor Rubovszky, Christian F Singer, Karoline Muehlbacher, Otto Metzger Filho, Theodora Goulioti, Ernest Law, Ann H Partridge, Lisa A Carey, Alex Zoroufy, Dominik Hlauschek, Christian Fesl, Erica L Mayer, Michael Gnant","doi":"10.1007/s10549-026-07896-7","DOIUrl":"10.1007/s10549-026-07896-7","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 2","pages":"12"},"PeriodicalIF":3.0,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.","authors":"Aixa E Soyano Muller, Dawn N Goodridge, Qianxing Mo, Junmin Whiting, Nazanin Khakpour, Marie Catherine Lee, Christine Laronga, Avan J Armaghani, Hyo Han, Hatem Soliman, Ricardo Costa, Loretta Loftus, Susan J Hoover, John V Kiluk, Zena Jameel, Brian J Czerniecki, Hung T Khong","doi":"10.1007/s10549-026-07912-w","DOIUrl":"10.1007/s10549-026-07912-w","url":null,"abstract":"<p><strong>Purpose: </strong>Hormone receptor-positive (HR+), HER2-negative breast cancer represents the most common subtype of breast cancer and is characterized by a risk of late recurrence. Neoadjuvant endocrine therapy with aromatase inhibitors (AIs) is a well-tolerated option in postmenopausal women; however, strategies to enhance its efficacy are needed. Combination of AI with immunotherapy is a promising approach. We evaluated the efficacy and safety of combining an AI with the anti-program death ligand 1 antibody durvalumab in the neoadjuvant setting.</p><p><strong>Methods: </strong>This single-arm, phase II study used a Simon two-stage design. Postmenopausal patients with early-stage HR+/HER2-negative breast cancer received durvalumab every 4 weeks plus daily AI for 6 months prior to surgery. The primary endpoint was the achievement of a modified Preoperative Endocrine Prognostic Index (mPEPI) score of 0.</p><p><strong>Results: </strong>Seventeen patients were enrolled and received durvalumab plus daily AI for six months before surgery. Treatment was well tolerated, with most adverse events being grade 1-2. A clinical complete response was seen in 58.8% of patients, although no pathologic complete responses occurred. Among the first 14 patients, one achieved mPEPI 0, which did not meet criteria to proceed to stage two. Overall, three patients (17.6%) achieved mPEPI 0.</p><p><strong>Conclusion: </strong>Neoadjuvant durvalumab plus AI was safe but demonstrated limited pathologic efficacy in this unselected HR + HER2-negative population. Favorable long-term outcomes support further investigation of immunoendocrine combinations in HR + HER2-negative breast cancer in biomarker-selected subgroups.</p><p><strong>Trial registration: </strong>NCT03874325. Date of registration. 12-03-2019.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"11"},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146199885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-effectiveness analysis of Mepitel Film for prevention of acute radiation dermatitis in breast cancer: a Canadian healthcare perspective.","authors":"Shirley S W Tse, Henry C Y Wong, Flay Charbonneau, Jeffrey Q Cao, Tarek Hijal, Marc Kerba, Mark R Waddle, Shing Fung Lee, Stephen T Sonis, Julie Ryan Wolf, Corina van den Hurk, Kimberly Corbin, Gustavo N Marta, Cindy Wong, Raymond J Chan, Patries M Herst, Rosemary Hill, Edward Chow, Hayeon Kim","doi":"10.1007/s10549-026-07920-w","DOIUrl":"10.1007/s10549-026-07920-w","url":null,"abstract":"<p><strong>Introduction: </strong>While randomized clinical trials (RCT) confirmed superiority of Mepitel Film (MF) in reducing acute radiation dermatitis (ARD) compared to standard-of-care (SoC), the incremental cost difference has limited its use. A cost-effectiveness analysis (CEA) was conducted from a Canadian healthcare payer's perspective to guide policy decisions.</p><p><strong>Methods: </strong>A decision model was constructed to perform a CEA for MF compared to SoC (moisturizers) for prevention of grade 2 or higher ARD following adjuvant hypo-fractionated whole-breast radiotherapy (RT) based on a Canadian multicentre RCT. Direct and indirect cost data were collected from two oncology centers in Canada. Quality-of-life (QoL) utility values were derived from mapping Dermatology Life Quality Index (DLQI) scores for patients with grade 2 or higher ARD at week 6 of RT to EQ-5D. A willingness-to-pay (WTF) threshold of CAD 50,000 per quality-adjusted life years (QALY) gained was used. Deterministic and probabilistic sensitivity analyses were performed to address uncertainty in decision model assumptions.</p><p><strong>Results: </strong>Base case analysis demonstrated that MF is cost-effective in preventing grade 2 or higher ARD as compared with SoC with an incremental cost-effectiveness ratio (ICER) of CAD 3366 per QALY gained. When indirect costs were included, MF resulted in an ICER of CAD 2823 per QALY gained. One-way sensitivity analysis showed that the results were most sensitive to the QoL utility value for ARD. Probabilistic sensitivity analysis confirmed that MF demonstrates 100% probability of cost-effectiveness at a $50,000 per QALY threshold.</p><p><strong>Conclusions: </strong>MF is a cost-effective intervention for preventing high-grade ARD and should be recommended for patients with breast cancer undergoing adjuvant RT.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"10"},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146199846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contrast-enhanced mammography-guided wire implantation: a cost-effective and reliable alternative for non-palpable contrast-enhanced imaging-only lesions.","authors":"Hulya Ozdemir, Umur Anil Pehlivan, Huseyin Ozgur Aytac","doi":"10.1007/s10549-026-07925-5","DOIUrl":"10.1007/s10549-026-07925-5","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"8"},"PeriodicalIF":3.0,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remote symptom monitoring with clinical alerts following lumpectomy: do alerts predict 30-day re-operation or re-admission rates?","authors":"Jennifer Wang, Solange Bayard, Melissa Assel, Minji Kim, Tracy-Ann Moo, Andrew J Vickers, Sigrid V Carlsson, Babak Mehrara, Monica Morrow, Jonas A Nelson, Audree B Tadros","doi":"10.1007/s10549-026-07905-9","DOIUrl":"10.1007/s10549-026-07905-9","url":null,"abstract":"<p><strong>Purpose: </strong>Electronic patient-reported outcomes (ePROs) are used postoperatively to detect complications through real-time symptom monitoring. This study examines whether alerts triggered through the \"Recovery Tracker\" (RT), an ePRO system, predict 30-day re-admission or re-operation after lumpectomy.</p><p><strong>Methods: </strong>We retrospectively reviewed breast cancer patients who underwent lumpectomy at a single institution between August 2018 and May 2024. Patients who completed RT surveys on postoperative days 1-5 were included. Symptom alerts categorized as red (urgent) and yellow (less urgent) were analyzed using generalized additive and univariable logistic regression models.</p><p><strong>Results: </strong>Among 8723 included patients, 2552 (29%) triggered at least one alert. Yellow alerts were more common than red across all days. Most red alerts were related to pain or vomiting; most yellow alerts were related to pain or wound redness. Overall, symptom severity and interference decreased over time. Triggering an alert was associated with increased risk of 30-day re-admission or re-operation (odds ratio [OR] 2.86, 95% confidence interval [CI] 1.64-5.03; p < 0.001). However, absolute event rates were low (re-admission 0.3%, re-operation 0.2%), and the absolute risk increase associated with any alert was minimal (0.7%, 95% CI 0.2%-1.1%).</p><p><strong>Conclusion: </strong>Although triggering at least one ePRO alert is associated with an increased relative risk for re-admission or re-operation, the absolute risk increase of re-admission and re-operation is very small. With enhanced follow-up by the clinical team among patients who trigger an alert, patients can be reassured that most symptoms will resolve on their own or can be treated with outpatient intervention.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"9"},"PeriodicalIF":3.0,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to editor on the article by K.‑H. Yoon et al., titled Impact of obesity on breast cancer recurrence by menopausal status and subtype.","authors":"A N Bharani, A Prateeksha, H P Samanvay","doi":"10.1007/s10549-026-07922-8","DOIUrl":"10.1007/s10549-026-07922-8","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"7"},"PeriodicalIF":3.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors.","authors":"Elise Martin, Mariam Chichua, Camila Kelly Chiodi, Petya Zyumbileva, Pietro Lapidari, Martina Pagliuca, Emma Gillanders, Aude Barbier, Aurélie Bertaut, Diane Boinon, Anne-Laure Martin, Sibille Everhard, Liliane Golli, Christelle Jouannaud, Courèche Kaderbhai, Benoîte Mery, Olivier Rigal, Maria Alice Franzoi, Ines Vaz-Luis, Antonio Di Meglio","doi":"10.1007/s10549-026-07904-w","DOIUrl":"10.1007/s10549-026-07904-w","url":null,"abstract":"<p><strong>Purpose: </strong>Longitudinal studies are essential for investigating outcome evolution among cancer survivors. However, longitudinal designs pose specific challenges, such as attrition and premature dropout. We aimed to assess experiences and perspectives on participation in longitudinal studies among survivors of early-stage breast cancer, and inform interventions aiming to reduce attrition.</p><p><strong>Methods: </strong>Motivation, facilitators, challenges, and perspectives regarding participation in a longitudinal study were qualitatively assessed via interviews and focus groups. A thematic content analysis was performed.</p><p><strong>Results: </strong>Between May and August 2023, 30 patients previously enrolled in the longitudinal CANTO cohort study (NCT01993498) were included: 17 participated in individual semi-structured interviews and 13 in two separate focus groups involving distinct participants. We identified four key themes: (1) joining the study as an expression of purpose and personal security, (2) ongoing engagement, as a response to flexible processes, a reassuring study environment, and personal commitment, (3) ongoing engagement, challenged by accumulating (practical and emotional) burdens and a reduced sense of connection to the study, and (4) participant-identified needs for a more supportive study experience. Findings emphasized the importance of enhancing communication with study participants, flexibility enabling decentralized participation, reducing burden of patient-generated data via repetitive questionnaires, supporting navigation of study procedures and minimizing the risk of a digital divide, and routinely disseminating study findings.</p><p><strong>Conclusion: </strong>These findings will inform strategies to reduce attrition and enhance the overall participant experience in longitudinal studies.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"4"},"PeriodicalIF":3.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12891045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146155999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic performance of thymidine kinase 1 activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with CDK4/6 and aromatase inhibitors.","authors":"Nicole L Brown, Sacha J Howell, Dimitrios Papantoniou, Olle Eriksson, Mattias Bergqvist, Amy Williams, Amy Kavanagh, Alexandra Backlund, Ahmed Albu-Kareem, Ellinor Elinder, Karolina Larsson, Monika Uminska, Maria Ekholm","doi":"10.1007/s10549-025-07879-0","DOIUrl":"10.1007/s10549-025-07879-0","url":null,"abstract":"<p><strong>Purpose: </strong>Thymidine kinase 1 activity (TKa) has previously been demonstrated as a prognostic biomarker for progression-free survival (PFS) in hormone receptor-positive, HER2-negative metastatic breast cancer (MBC), but its optimal use remains undefined. This study evaluated the prognostic performance of TKa across multiple sampling time points and thresholds in patients receiving first-line CDK4/6 inhibitor plus aromatase inhibitor therapy.</p><p><strong>Methods: </strong>TKa was measured (DiviTum® assay) at baseline (BL), cycle 1 day 15 (C1D15), and cycle 2 day 1 (C2D1) in patients enrolled in the PDM-MBC study (n = 90). Thresholds for PFS discrimination were identified using maximally selected rank statistics, with predefined cut-offs tested for comparison. Prognostic performance was assessed using the corrected Akaike information criterion (AICc) and Harrell's concordance index (C-index).</p><p><strong>Results: </strong>TKa was prognostic at all time points. Data-derived thresholds identified groups with differing PFS and overall survival (OS), and predefined cut-offs (≥ 50, ≥ 100, ≥ 250 DiviTum® units of Activity [DuA]) also discriminated survival outcomes. BL and C2D1 models performed better than C1D15 and comparably to multi-time-point models. Among patients with BL TKa ≥ 250 DuA, suppression to < 100 DuA at C1D15 was associated with longer median PFS (23.9 vs. 10.3 months; p = 0.034).</p><p><strong>Conclusion: </strong>Baseline TKa provides prognostic information, with potential added value from repeated testing in those with high baseline levels. TKa behaves as a continuous biomarker of risk, and continuous modelling may offer more clinically informative individual risk estimation, while thresholds may retain value for specific clinical contexts. Validation in larger cohorts is warranted to support integration into routine practice.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"6"},"PeriodicalIF":3.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146155949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer.","authors":"Madelyn F Klugman, Maya Aboumrad, Ruizhe Chen, Catherine H Marshall, Jenna V Canzoniero, Antonio C Wolff, Kala Visvanathan","doi":"10.1007/s10549-025-07872-7","DOIUrl":"10.1007/s10549-025-07872-7","url":null,"abstract":"<p><strong>Background: </strong>Prognostic factors and treatment outcomes have been identified in estrogen receptor (ER) low-positive early-stage breast cancer. This study evaluates outcomes in ER low-positive de novo metastatic breast cancer (dnMBC) patients.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of adults with human epidermal receptor-2 negative dnMBC diagnosed from 2018 to 2021 in the National Cancer Database. We classified ER status as negative (< 1%), low-positive (1-10%), or positive (11-100%). We compared overall survival by ER status using Cox regression, adjusting for age, metastatic sites, race/ethnicity, comorbidities, insurance, and treatment receipt. We then analyzed the cohort with ER low-positive patients stratified by progesterone receptor (PR) status, defined as negative (< 1%) or positive (1-100%). Among ER low-positive patients, we evaluated survival by first-course treatment. We distinguished cytotoxic chemotherapy from cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) therapy based on the timing of endocrine therapy and chemotherapy.</p><p><strong>Results: </strong>Among 27,672 patients, 3% had ER low-positive dnMBC. ER low-positive/PR-positive patients had longer median (95% CI) survival [19.8 (14.8-24.8) months] compared to both ER low-positive/PR-negative [11.8 (10.6-13.5) months] and ER-negative [12.9 (12.5-13.6) months] patients. ER low-positive/PR-positive patients had decreased risk of death compared to ER-negative patients (hazard ratio = 0.84, 95% CI 0.71-1.00), while ER low-positive/PR-negative patients did not. ER low-positive dnMBC patients who received chemotherapy followed by endocrine therapy (± CDK4/6i) or endocrine therapy + CDK4/6i had improved or similar survival compared to patients who received chemotherapy alone.</p><p><strong>Conclusions: </strong>PR-positivity identifies a subgroup of ER low-positive dnMBC patients with superior survival compared to ER-negative patients. First-line treatment incorporating endocrine therapy may be appropriate to consider for ER low-positive patients.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"5"},"PeriodicalIF":3.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146155969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.","authors":"Kristina Parsons, Hui Yin, Oriana H Y Yu, Farzin Khosrow-Khavar, Laurent Azoulay","doi":"10.1007/s10549-026-07913-9","DOIUrl":"10.1007/s10549-026-07913-9","url":null,"abstract":"<p><strong>Purpose: </strong>The objective of this study was to determine whether pre-existing type 2 diabetes is associated with an increased risk of breast cancer-related and all-cause mortality, compared with non-diabetes, and if the risk varies across glycated hemoglobin A1c (HbA1c) categories.</p><p><strong>Methods: </strong>Using the Clinical Practice Research Datalink, we assembled a cohort of patients at least 18 years old, newly diagnosed with invasive breast cancer between 1998 and 2020, with follow-up until March 2021. Patients were followed from 3 months after breast cancer diagnosis until one of the study outcomes, end of registration with the general practice, or end of study. Multivariable Cox proportional hazards models, adjusted for 33 confounders, were fitted to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer-related and all-cause mortality, comparing patients with and without type 2 diabetes among patients with and without metastatic breast cancer. In a secondary analysis, HRs for the outcomes were estimated across glycated HbA1c categories.</p><p><strong>Results: </strong>The cohort included 157,298 patients with incident breast cancer. Among patients with non-metastatic breast cancer (n = 125,268), type 2 diabetes was associated with a 12% increased risk of breast cancer mortality and 21% increased risk of all-cause mortality. Among patients with metastatic breast cancer (n = 32,030), type 2 diabetes was associated with a 22% increased risk of breast cancer mortality and a 24% increased risk of all-cause mortality. The secondary analysis showed that higher glycated HbA1c was associated with an increased risk, in both the non-metastatic and metastatic cohorts.</p><p><strong>Conclusion: </strong>In this large population-based cohort study, type 2 diabetes was associated with a greater risk of breast cancer-related and all-cause mortality, with an increased risk among patients with type 2 diabetes in the highest glycated HbA1c categories, compared to non-diabetes.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 1","pages":"3"},"PeriodicalIF":3.0,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146141180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}